国产v亚洲v欧美v专区-国产v亚洲v日韩v欧美v中文网-国产v亚洲v天-国产v亚洲v天堂a无码-国产v亚洲v天堂a无码99-国产v亚洲v天堂无码

Molecular immunology department

Molecular immunology department owns everal technology platforms including ELISA/ELISpot, reverse dot blot, and time- resolved fluorescence. The product lines developed can be used for TB infection screening, diagnosis and detection of drug resistance. Among them is the tuberculosis T cell immune detection kit with independent intellectual property (patented in China), which has won CFDA clinical approval and production license; the in- development kit for rapid diagnosis of tuberculosis drug sensitivity based on reverse dot blot will help to achieve an all- round and rapid detection of MDR- TB; the in- development tuberculosis molecular diagnostic kit is simple to use and does not require any special equipment, suitable for the needs of tuberculosis prevention and control at all levels of disease control facilities.
    Molecular immunology department has taken part in the major projects of the 12th five- year plan and has established a long- term cooperation with Institute of Microbiology of Chinese Academy of Sciences, Peking University, Tsinghua University, Chinese Center for Disease Control and Prevention and Beijing Chest Hospital. The platform established for the conversion of biological reagents ensures sustained innovation of the product lines.

分子診斷部

分子診斷部以microRNA為切入點，專注于重大癌癥、艾滋病、結核病、肝病等microRNA診斷試劑盒的研制，并提供從microRNA表達譜檢測到功能研究的全套技術服務。本平臺采用自主知識產權發明專利"三步法qPCR"技術和獨特的外源RNA對照設計，實現血清、血漿、組織、細胞、石蠟組織切片中microRNA表達量的檢測。

艾滋病快速進展microRNA標志物已申報獲得5項國家發明專利，乳腺癌特異性microRNA標志物已申報獲得4項國家發明專利，乙肝、肝硬化特異性microRNA標志物已申報3項國家發明專利，肝硬化miRNA診斷試劑盒已啟動注冊申報程序。